Comparative pharmacokinetics and insulin action for three rapid-acting insulin
analogs injected subcutaneously with and without hyaluronidase.
Author(s): Morrow L(1), Muchmore DB, Hompesch M, Ludington EA, Vaughn DE.
Affiliation(s): Author information:
(1)Profil Institute for Clinical Research, Chula Vista, CA, USA.
Publication date & source: 2013, Diabetes Care. , 36(2):273-5
OBJECTIVE: To compare the pharmacokinetics and glucodynamics of three
rapid-acting insulin analogs (aspart, glulisine, and lispro) injected
subcutaneously with or without recombinant human hyaluronidase (rHuPH20).
RESEARCH DESIGN AND METHODS: This double-blind six-way crossover euglycemic
glucose clamp study was conducted in 14 healthy volunteers. Each analog was
injected subcutaneously (0.15 units/kg) with or without rHuPH20.
RESULTS: The commercial formulations had comparable insulin time-exposure and
time-action profiles as follows: 50% exposure at 123-131 min and 50% total
glucose infused at 183-186 min. With rHuPH20, the analogs had faster yet still
comparable profiles: 50% exposure at 71-79 min and 50% glucose infused at 127-140
min. The accelerated absorption with rHuPH20 led to twice the exposure in the
first hour and half the exposure beyond 2 h, which resulted in 13- to 25-min
faster onset and 40- to 49-min shorter mean duration of insulin action.
CONCLUSIONS: Coinjection of rHuPH20 with rapid-acting analogs accelerated insulin
exposure, producing an ultra-rapid time-action profile with a faster onset and
shorter duration of insulin action.
|